Medication-Related Osteonecrosis of the Jaw (MRONJ)

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious complication of potent antiresorptive therapy (nitrogen-containing bisphosphonates and denosumab) and certain antiangiogenic agents. It is defined by exposed or probeable necrotic bone in the maxillofacial region that persists for greater than 8 weeks in a patient with relevant drug exposure and without prior jaw radiotherapy. The condition was first recognised with intravenous bisphosphonates used in oncology (zoledronic acid, pamidronate) and later with denosumab; it also occurs, at much lower rates, with oral bisphosphonates for osteoporosis and with some targeted cancer therapies.

The clinical burden falls almost entirely on patients receiving high-dose intravenous or subcutaneous antiresorptives for skeletal metastases or multiple myeloma. In this group the incidence after dental extraction can reach several percent; in osteoporosis patients on oral agents the absolute risk is orders of magnitude lower (often cited less than 1 in 10,000 patient-years). The posterior mandible is the most common site because of its high bone turnover, thin overlying mucosa, and relatively terminal blood supply.

For the exam the essential threads are: the precise definition and staging (AAOMS), why antiresorptives cause it (impaired osteoclast-mediated repair after trauma), the central role of dental extraction as trigger, the radiographic signs that distinguish it from metastasis or simple osteomyelitis, and the management ladder from prevention through conservative care to resection in advanced disease. Drug holidays before extraction remain controversial and are not a substitute for pre-therapy dental optimisation.

MRONJ is fundamentally a failure of bone repair after trauma in the setting of osteoclast suppression. Antiresorptives (amino-bisphosphonates via FPPS inhibition in the mevalonate pathway; denosumab via RANKL blockade) drastically reduce osteoclast number and activity. In most of the skeleton this is therapeutic (reduced fracture risk), but the jaws experience repeated low-level trauma from mastication, periodontal disease, and especially dental procedures. When an extraction socket or mucosal breach occurs, the normal sequence of inflammation followed by osteoclast-mediated resorption of damaged bone and osteoblast-driven new bone formation is interrupted. The result is persistent devitalised bone that becomes exposed when overlying soft tissue cannot heal over it.

Additional amplifying factors include antiangiogenic effects (reduced blood supply for healing), secondary bacterial colonisation (Actinomyces and oral flora), and in cancer patients the cumulative insults of chemotherapy, steroids, malnutrition, and the underlying malignancy. The posterior mandible is disproportionately affected because of high baseline turnover in alveolar bone, thin mucosa, and relatively limited collateral circulation once the inferior alveolar artery is compromised.

The clinical corollary is that prevention (optimising the dentition before the first high-risk dose) is vastly more effective than any treatment after exposure has occurred. Once necrotic bone is exposed, management is staged and largely supportive until sequestra separate or surgical resection is required for complications.

The jaws (particularly the mandible) are uniquely vulnerable. The mandible has a high rate of bone remodeling, especially in the alveolar process that supports teeth. When teeth are extracted the socket must heal by a coordinated sequence of inflammation, granulation, woven bone formation, and remodeling. Potent antiresorptives suppress osteoclast recruitment and function, so the remodeling phase stalls. The result is devitalised bone that becomes exposed when the thin mucosa breaks down or after surgical trauma.

Key anatomic points:

• Mandible is affected far more often than maxilla (roughly 2 to 3:1 or higher in most series).
• Posterior mandible (molar and premolar regions) is the classic site; the thin mucosa over the mylohyoid ridge and the limited collateral circulation make it susceptible.
• The inferior alveolar nerve can be involved, producing numbness or paraesthesia when necrosis reaches the canal.
• Maxillary cases are more likely to present with oro-antral fistula or sinusitis because of the thin bone and proximity to the antrum.

Pathophysiology is multifactorial:

• Osteoclast inhibition (via farnesyl pyrophosphate synthase blockade for amino-bisphosphonates; RANKL neutralisation for denosumab) prevents the normal repair of micro-damage and the resorption of necrotic bone.
• Antiangiogenic effects (seen with some bisphosphonates and with agents such as bevacizumab) reduce vascularity and healing capacity.
• Local trauma (extraction, ill-fitting dentures, periodontal surgery) creates a wound that cannot epithelialise over the non-viable bone.
• Secondary infection (Actinomyces and mixed oral flora are frequently cultured) perpetuates inflammation and bone death.
• In cancer patients, the underlying disease, chemotherapy, steroids, and poor nutrition compound the problem.

Spontaneous MRONJ (no obvious dental trigger) occurs, especially in the mylohyoid region or torus, but extraction or other invasive procedures remain the dominant precipitant in reported series.

The AAOMS staging system (updated 2014 and with further clarification in 2022) is the international standard used in examinations and in multidisciplinary discussion. It is clinical-radiographic and directly guides treatment.

History

• Current or previous bisphosphonate (zoledronate, alendronate, risedronate, pamidronate, ibandronate) or denosumab, or antiangiogenic therapy (bevacizumab, sunitinib, etc.).
• Oncology indication (bone metastases, multiple myeloma, giant cell tumour) versus osteoporosis or Paget disease.
• Recent dental extraction, implant, periodontal surgery, or denture trauma - timing relative to drug exposure is critical.
• Pain, swelling, bad taste, halitosis, discharge, or a non-healing socket that has persisted beyond the expected 4 to 6 weeks.
• Numbness of the lower lip or chin (inferior alveolar nerve involvement).

Examination

• Exposed bone in the oral cavity, often with a yellow-white or grey sequestrum; the surrounding mucosa may be erythematous or rolled.
• A fistula (intraoral or extraoral) that can be probed to bone or to a sequestrum.
• Signs of infection: pus, swelling, trismus, lymphadenopathy.
• Pathologic fracture: mobile mandible segments, malocclusion, pain on loading.
• Extraoral cutaneous fistula or exposed bone through skin in advanced cases.
• Dental status: caries, periodontal pocketing, ill-fitting prostheses.

Always examine both jaws, the full dentition, and the neck. Bilateral or multifocal disease occurs, especially in high-dose intravenous therapy.

Imaging

• Panoramic radiograph (orthopantomogram) is the first-line study: look for poorly defined radiolucencies, sclerotic zones, sequestra (dense fragments separated by lucent rims), moth-eaten destruction, and periosteal reaction.
• Cone-beam CT (CBCT) or conventional CT provides better three-dimensional assessment of extent, cortical perforation, involvement of the inferior alveolar canal, and proximity to the maxillary sinus.
• MRI is useful when soft-tissue extent or marrow involvement needs clarification, or when ruling out metastatic disease or osteomyelitis.
• Bone scintigraphy or PET can show increased uptake but is non-specific; useful in selected cases to assess whole-skeleton burden or occult sites.

Laboratory

• No specific blood test diagnoses MRONJ. Check full blood count, inflammatory markers (CRP, ESR), and albumin/pre-albumin if nutrition is a concern.
• In oncology patients, coordinate with the medical oncology team regarding renal function (especially before any further zoledronate) and calcium (hypocalcaemia risk with denosumab).
• Microbiology: swab or biopsy of exposed bone or pus for culture and sensitivity; Actinomyces is frequently isolated but its role as primary pathogen versus coloniser is debated.

Biopsy / histology

• Not required for every case. When performed (to exclude metastasis or primary malignancy), histology shows necrotic bone with empty lacunae, bacterial colonisation, and minimal inflammatory infiltrate in pure MRONJ; vital bone at the resection margin confirms adequacy.
• Always send tissue in stage 3 surgical cases.

Differential diagnosis

• Metastatic carcinoma (breast, prostate, lung, myeloma) - can coexist with MRONJ.
• Osteoradionecrosis (if radiation history).
• Chronic osteomyelitis (no drug history).
• Primary bone tumours or osteonecrosis from other causes (rare).

View larger

View larger

View larger

Prevention (the only intervention with level-1 impact)

• All patients due to start high-risk intravenous or subcutaneous antiresorptive or antiangiogenic therapy for cancer should have a dental review before the first dose.
• Extract non-restorable teeth and complete periodontal therapy; allow 4 to 6 weeks of mucosal healing before commencing the drug when clinically safe.
• For patients already on therapy who require extraction, primary closure, perioperative antibiotics, and chlorhexidine are used; risk cannot be eliminated.
• Patient education: report any non-healing socket, pain, or exposed bone immediately.

Stage-directed treatment

• Stage 0 and 1: conservative. Chlorhexidine 0.12 percent rinses twice daily, meticulous oral hygiene, regular review. No elective surgery. Mobile sequestra may be removed if they are easily accessed without further trauma.
• Stage 2: add infection control. Empirical or culture-directed oral antibiotics (amoxicillin-clavulanate 875/125 mg twice daily or clindamycin 300 mg three times daily for 7 to 14 days), antiseptic rinses, pain management, and limited debridement of loose bone only. Most cases stabilise; some progress.
• Stage 3: surgical resection. Under general anaesthesia, resect all necrotic bone back to bleeding, viable bone margins (marginal mandibulectomy if inferior border intact; segmental if not). Stabilise with reconstruction plate; consider free fibula or scapula flap for large defects in fit patients. Continue antibiotics and chlorhexidine postoperatively. Long-term follow-up is mandatory.

Drug holiday

• The 2014 and later AAOMS guidance does not recommend routine drug interruption solely for MRONJ prevention in patients who need ongoing skeletal protection. Individualised discussion with the oncologist is required. For osteoporosis patients on long-term oral therapy, a drug holiday may be considered for other reasons (atypical fracture risk) but is not proven to reduce MRONJ.

Supportive measures

• Nutrition, smoking cessation, glycaemic control in diabetics, and management of comorbidities improve healing potential.
• Hyperbaric oxygen is not routinely recommended by AAOMS for MRONJ (unlike ORN); evidence is weak.

Both drugs suppress osteoclasts and both cause MRONJ, but they do so by different mechanisms with very different kinetics - and that difference is the basic-science reason a "drug holiday" behaves so differently between them.

A further denosumab-specific caveat is the rebound phenomenon: stopping denosumab without transitioning to a bisphosphonate causes rapid loss of the accrued bone density and a risk of multiple rebound vertebral fractures - so cessation decisions are never the dentist's alone and must involve the prescribing physician.

Local

• Chronic pain, recurrent infection, and halitosis.
• Pathologic fracture of the mandible (most feared stage 3 event).
• Oro-cutaneous fistula, oro-antral communication, maxillary sinusitis.
• Inferior alveolar or lingual nerve injury (from disease or surgery).
• Loss of teeth, denture intolerance, and severe functional impairment.

Systemic

• In frail oncology patients, uncontrolled jaw sepsis can contribute to systemic inflammatory response or delay cancer treatment.
• Malnutrition from pain on eating.

Treatment-related

• Surgical complications: plate exposure, flap failure, further necrosis at margins, donor-site morbidity.
• Antibiotic-associated diarrhoea or resistance with prolonged courses.
• Psychological impact of facial disfigurement or prolonged illness in patients already facing cancer.

Late failure

• Recurrence of exposed bone at the resection margin or at distant sites if the underlying drug exposure and risk factors continue.

The topic's definition deliberately excludes prior jaw radiation - because necrotic exposed jaw bone in an irradiated patient is osteoradionecrosis (ORN), a separate entity that looks similar but differs in cause, mechanism, and (critically) the role of hyperbaric oxygen.

Because the two are defined to be mutually exclusive, the single discriminating question is the radiation history: an antiresorptive patient with no jaw radiation has MRONJ; an irradiated patient has ORN even if also on a bisphosphonate. The distinction matters because hyperbaric oxygen helps ORN but is not a standard MRONJ treatment.

MRONJ sits at the intersection of oncology, oral surgery, and orthopaedic/metabolic bone medicine. Every patient who starts a high-potency antiresorptive for skeletal metastases or myeloma should be viewed as having a lifelong risk to the jaws. The orthopaedic surgeon or endocrinologist who prescribes these agents must either arrange pre-treatment dental clearance or document that the patient has been counselled and that dental review has occurred or is planned.

In the exam, the topic tests understanding of:

• Basic bone biology (osteoclast function, remodeling, angiogenesis).
• Risk stratification by drug, dose, route, and indication.
• Practical prevention rather than heroic salvage.
• Clear staging language that communicates urgency to the maxillofacial team.
• The limits of conservative care and the indications for resection.

The same principles apply to denosumab as to bisphosphonates; the RANKL inhibitor produces a comparable, if not higher, incidence of MRONJ in oncology doses. As more patients receive these therapies for longer periods and for additional indications (giant cell tumour, osteoporosis with high fracture risk), the absolute number of MRONJ cases will remain clinically relevant even if the per-patient risk is managed.

• AAOMS position papers (2007, 2009, 2014, 2022 updates) remain the most widely referenced international guidance. They established the current definition, the four-stage system, and the emphasis on prevention before high-risk therapy. The 2014 paper broadened the term from BRONJ to MRONJ to include denosumab and antiangiogenics.

• European / international consensus (e.g. from ESMO, MASCC, and national oral medicine societies) aligns closely with AAOMS on staging and the central role of pre-treatment dental assessment for patients starting oncology-dose antiresorptives. Some European guidelines place slightly more weight on drug holidays in selected low-risk scenarios, but evidence remains limited.

• Denosumab-specific data: oncology-dose denosumab (120 mg monthly) carries a comparable or slightly higher MRONJ incidence than zoledronic acid in head-to-head trials and real-world cohorts. The same prevention and staging principles apply.

• Registry and cohort evidence: large oncology cohorts and systematic reviews (including the 20-year single-centre series and extraction-risk meta-analyses) confirm that dental extraction is the dominant modifiable risk factor and that structured prevention programs reduce incidence. Absolute risk in osteoporosis patients on oral agents remains very low worldwide.

• Global practice variation: access to specialist maxillofacial care, CBCT, and reconstructive microsurgery varies. In resource-limited settings, emphasis remains on prevention and conservative infection control; advanced stage 3 disease may be managed with local debridement and antibiotics rather than major resection. No country-specific billing codes are used in guidance.

• Key practical message: wherever a patient is started on high-potency antiresorptive therapy for cancer, dental review before the first dose is a quality and safety standard across AAOMS, European, and Asia-Pacific recommendations.